Compare iShares Core MSCI Emerging Markets ETF (IEMG) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core MSCI Emerging Markets ETF vs BIO-TECHNE Corp — how do they compare? iShares Core MSCI Emerging Markets ETF trades at $80.75 (market cap $164.02B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: iShares Core MSCI Emerging Markets ETF is far larger — about 14.4× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while iShares Core MSCI Emerging Markets ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core MSCI Emerging Markets ETF for 57 Days and BIO-TECHNE Corp for 63 Days on average.
| IEMG | TECH | |
|---|---|---|
Market Cap | $164.02B | $11.37B |
Volume | 7,876,071 | 3,153,511 |
Sector | Broad Market / Factor | Health |
52-Week High | $86.00 | $72.61 |
52-Week Low | $64.22 | $43.31 |
Typical Hold Time | 57 Days | 63 Days |
Enterprise Value | — | $11.40B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEMG trades at $82.04, down 1.2% on the day, with a bullish technical signal from moving averages while oscillators remain neutral. The emerging markets ETF has shown strong performance compared to peers, with recent articles highlighting its 35% one-year returns and 39% technology sector weighting. Support levels cluster around $81-82 with resistance at $83.
The outlook remains positive given emerging markets' recent outperformance and record capital inflows, though investors face volatility risks from concentrated tech exposure and currency fluctuations. The fund's 0.09% expense ratio provides cost-efficient emerging markets access, but competitors offer lower fees for broader international exposure.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core MSCI Emerging Markets ETF
IEMG tracks the MSCI Emerging Markets Investable Market Index, providing broad exposure to large, mid, and small-cap stocks across over 20 emerging market countries. It is designed as a low-cost core holding for investors seeking diversified growth from economies outside of developed markets.
Read more on IEMG →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
